November 4, 2008
Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board
A Strong International Strategy for Invisicare Is Put In Place
Las Vegas, Nevada - November 4th, 2008 - Skinvisible, Inc. (SKVI:OTCBB), the developers of Invisicare, a patented polymer delivery system that enhances topically applied products, today announced the appointment of Geert Cauwenbergh, PhD to head its International Advisory Board and to spear-head a focused strategy to expand the demand for Invisicare in international markets. Dr. Cauwenbergh has vast international experience in the dermatology market including research, development and the successful commercialization of pharmaceutical products with Barrier Therapeutics, Johnson and Johnson (NYSE: JNJ) and Janssen Pharmaceutica.
Dr. Cauwenbergh's career has been focused in dermatology. Early in his career he was the International Director of Clinical R&D, Dermatology and Infectious Diseases at the Janssen Research Foundation at Janssen Pharmaceutica in Belgium. This was followed with executive roles at Johnson & Johnson (J&J) including VP Research & Development for J&J Consumer Companies Worldwide, VP Product Development, as well as serving on the J&J Consumer Company's Management Board and Director of J&J' s Corporate Skin Care Council.
In 2001 he founded Barrier Therapeutics with offices in the US and Belgium, raising over $250 million in venture capital as well as a listing on the NASDAQ stock exchange. He developed a portfolio of dermatology products, taking the company to annual sales exceeding $45 million until it was recently acquired by Stiefel Laboratories, Inc.
In August Dr. Cauwenbergh took on the role of CEO of RHEI Pharmaceuticals, a specialty pharmaceutical company with operations in Belgium, the U.S. and China. RHEI develops and commercializes pharmaceutical products for the Chinese market. Dr. Cauwenbergh has authored over 100 publications and co-authored several books. He received his Ph.D. in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, in Belgium.
"We are very pleased to have Dr. Cauwenbergh on our international advisory board," said Mr. Terry Howlett, President and CEO of Skinvisible, Inc. "He brings an abundant amount of knowledge and experience that can assist us in implementing an aggressive expansion strategy into international markets, particularly China and Europe."
"I am very pleased to be advising Skinvisible on their international efforts", said Dr. Cauwenbergh. "High development costs coupled with the extensive time required to get new products to market is almost prohibitive today. Many pharmaceutical companies are looking at ways to offer Life Cycle Management to their existing portfolio, particularly companies with products coming off patent. Skinvisible offers these companies the opportunity to develop new products by combining their existing active ingredients with the Invisicare polymer delivery system which offers new innovative benefits like a controlled release, superior adherence and most importantly, an opportunity for a new patent; - benefits the generic competitors cannot offer."
About Invisicare®
Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com
Forward-Looking Statements:
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2008)
|
Press Release Index
Click here to join our mailing list.
|
Skinvisible Web